Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aptevo Therapeutics Provides Corporate and Pipeline Update

Reports Record Quarterly IXINITY Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Introduces New Adaptir(TM) Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific

APVO : 0.58 (+1.75%)
Technological Advancements Aid Medical Practitioners in Combatting Cancer

In 2018, there was an estimated 1.73 million new cancer cases diagnosed and 609,640 cancer deaths in the U.S., according to the American Cancer Society. The ACS does not expect cancer rates to slow down...

ONPH : 0.0350 (unch)
UEEC : 1.3700 (+0.74%)
AVEO : 0.82 (unch)
APVO : 0.58 (+1.75%)
SLS : 0.13 (unch)
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results

Reports Positive Preliminary Top-Line Safety Data for APVO210

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol...

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients

Expands Options for Patients with Potential for

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Reports First Quarter 2019 Financial Results

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY(R) Net Revenue

APVO : 0.58 (+1.75%)
5 Stocks to Gain From Dollar's Recent Strength

The U.S. dollar hits an almost 2-year record high as global central banks turn dovish and German business moral deteriorates.

BFIN : 11.93 (+0.76%)
HIIQ : 27.25 (+1.76%)
APVO : 0.58 (+1.75%)
ADES : 13.96 (+2.20%)
GTIM : 1.83 (-1.61%)
Research Report Identifies Fastenal, Ideal Power, Fuel Tech, CTI BioPharma, Aptevo Therapeutics, and Caseys General Stores with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fastenal Company (NASDAQ:FAST),...

FAST : 35.77 (+0.99%)
IPWR : 2.20 (-22.81%)
FTEK : 0.97 (unch)
CTIC : 0.77 (+1.32%)
APVO : 0.58 (+1.75%)
CASY : 160.82 (-0.32%)
Aptevo Therapeutics Reports IXINITY(R) and Pipeline Progress

Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation...

APVO : 0.58 (+1.75%)
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR(TM)...

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY Net Revenue of $23.1 Million Representing 111% Increase Over 2017

APVO : 0.58 (+1.75%)
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APVO : 0.58 (+1.75%)
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering...

APVO : 0.58 (+1.75%)
Aptevo Announces Proposed Public Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject...

APVO : 0.58 (+1.75%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -1.53 , AIZ -0.07 , SBAC -2.58 , SO -0.16 , WELL -0.93
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar